Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.nektar.com
Nektar Therapeutics News Releases
Get the latest updates from Nektar Therapeutics News Releases directly as they happen.
Follow now 76 followers
Latest posts
Last updated about 1 month ago
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
about 1 month ago
Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both...
Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
about 2 months ago
SAN FRANCISCO, March 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced...
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
about 2 months ago
SAN FRANCISCO, March 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today...
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago
SAN FRANCISCO, March 6, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today...
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
2 months ago
SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will...
Nektar Therapeutics to Participate in Two Investor Conferences in March
2 months ago
SAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today...
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
3 months ago
SAN FRANCISCO, Feb. 17, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today...
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
3 months ago
SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a...
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering
3 months ago
SAN FRANCISCO, Feb. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a...
Nektar Therapeutics Announces Proposed Public Offering
3 months ago
SAN FRANCISCO, Feb. 10, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a...
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
3 months ago
71% and 83% of patients maintained EASI -75 responses and 85% and...
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
3 months ago
SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a...